Amanda’s current research interests include the use of real world evidence to support HTA and product development; novel pricing and reimbursement mechanisms for pharmaceuticals (e.g. managed entry agreements and the economics of indication-based pricing); health state valuation methodology; criteria for the economic evaluation of health interventions; and the interaction between HTA policy and optimal R&D decisions by industry
Before joining OHE in 2014, Amanda was a research fellow at the University of Birmingham where she focused on the HTA of medical devices. She was involved in projects commissioned by the National Institute for Health and Care Excellence (NICE), and also conducted research on approaches to embedding health economic evaluation early in the product development process.
Amanda holds a PhD in health economics from the University of Birmingham.